Evolus, which is preparing to launch a biosimilar version of botox, filed on Tuesday with the SEC to raise up to $75 million in an initial public offering.
The Irvine, CA-based company was founded in 2012 and plans to list on the Nasdaq under the symbol EOLS. Evolus filed confidentially on August 28, 2017. Cantor Fitzgerald and Mizuho Securities are the joint bookrunners on the deal. No pricing terms were disclosed.
